Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding share plan transactions rather than a financial performance report.
Material Changes
The filing details increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for specific individuals following the notional re-investment of the dividend paid on October 2, 2014. The transaction prices were 1404.00 pence per Ordinary Share and $45.63 per ADS.
- Dr M M Slaoui: Connected person Dr K Slaoui received an increase of 87.087 ADSs.
- Mr P C Thomson: Received an increase of 85.297 Ordinary Shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Plan holdings that vest following the end of the relevant measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the vesting schedule and measurement period for the GlaxoSmithKline 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares or ADSs held by the named directors and connected persons post-transaction.
- Review the dividend payment date of October 2, 2014, to ensure alignment with the re-investment timing.